VALO Health Raises $110M in Series B Funding

Boston-based Valo Health Raises $300m Series B To Identify Molecules And Predict Their Ability To Be Used In Drugs (Daniel Mccoy/Wichita Business Journal)- Koch Disruptive Technologies has invested $110 million in a Boston-based company improving drug delivery.

A Boston, MA-based technology company focused on improving drug discovery and development has received a $110 million investment from Koch Disruptive Technologies (KDT). Additionally, the company closed its Series B round at $300m, bringing its total funding to over $450m. Funds will be used for scaling the Opal Computational Platform, working capital, and other general purposes.

Founded and led by David Berry, VALO Health provides the Opal Computational PlatformTM, which combines machine learning capabilities with patient data to develop therapeutic programs.

Through Opal, VALO scientists have identified associations between genetic markers and disease. This has enabled them to identify specific genes involved in gene activity. This initial focus has been on oncology, neurodegenerative, and cardiovascular diseases. 

Founded by Flagship Pioneering, the company also has offices in Lexington, MA, San Francisco, CA, Princeton, NJ, and Branford, CT.

Read more latest News – In The Uk, A 5g Spectrum Auction Raises 1.23 Billion Euros